Loading…
← CockpitCompetitor Analysis › CADL Candel Therapeutics, Inc.Open in the cockpit ↗

Candel Therapeutics, Inc.CADLCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology
Momentum laggard 7
Mkt cap
$417M
US dollars, full cap
Free float
80%
of shares outstanding
$/day
$11.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · USD$5.32
1D-1.5%
1W-42.3%
1M-38.4%
3M-56.9%
6M-31.0%
YTD-5.8%
1Y+12.5%
ATR %14.6%
Beta2.14
52w lowhigh62.0% off high

What Candel Therapeutics does

Employees: 55

Candel Therapeutics at a glance

Size Candel Therapeutics (CADL) is a United States Health Care company (Biotechnology) with a market value of $417M, the 2806th largest of 3,085 United States companies the cockpit tracks. Shares closed at $5.32 on 18 Nov 2026.

Performance Over six months the shares fell 31.0%, against -22.0% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 21 in its peer set.

Short interest Short interest is 17.1% of the free float (30 Oct 2026).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 2026Peer median 78CADL 67
Six months, rebased to 100: Candel Therapeutics against the median of its 20 peers (local-currency closes).

Candel Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$125,000
Revenue growth———-100%—
Gross profit-$683,000-$845,000-$990,000-$1.20M-$862,000
EBITDA-$81.1M-$47.4M-$32.4M-$37.2M-$33.7M
Net income-$99.1M-$38.2M-$55.2M-$37.9M-$18.8M
Free cash flow-$70.2M-$38.9M-$27.0M-$34.7M-$32.7M
Capital expenditure$1.29M$587,000$16,000$457,000$1.30M
Total debt$49.8M$49.0M$13.5M$22.8M$22.8M

Quarterly statements and history in the cockpit →

Candel Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%476830456160688163EPRX68823868831765476998337867122509PRTA116768809817896037390007102480IRLA300683CADL6-month return →1-month return →
Up and to the right = strong over both horizons. Candel Therapeutics is the large dot.

Candel Therapeutics competitors and peer comparison

How Candel Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Candel Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureCADLPeer medianRank in peer set
1-month return-38.4%-13.4%lowest of 21
6-month return-31.0%-22.0%7th lowest of 21
Distance from 52-week high-62.0%-41.5%4th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Qingdao Vland Biotech 603739.SSChina$437M-24%+5%7%2.2×7.7%+7.3%
Berry Genomics 000710.SZChina$439M-17%-2%-24%3.3×n/an/a
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
IRulya Therapeutics IRLAUnited States$440M+88%n/an/an/an/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a

Questions

Which companies are Candel Therapeutics's closest peers?
The cockpit's peer set: Rznomics (476830.KS), G2GBIO (456160.KS), Shanghai Serum Bio-Technology (688163.SS), Eupraxia Pharmaceuticals (EPRX.TO), Shanghai Obio Technology (Group) (688238.SS), Shanghai ZJ Bio-Tech (688317.SS), Medigen Vaccine Biologics (6547.TWO), Edding Genor (6998.HK).
How has Candel Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -31.0% against -22.0% for the median peer; over one year +12.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.